Primary appointment at IUSM Department of Emergency Medicine
Secondary appointments at IUPUI and Purdue in Biomedical Engineering
Safer Clot Lysis Through Nanoparticle Delivery of Direct Fibrinolytic Agents
Being a Chemical and Biomolecular Engineer and the first tenure track PhD faculty member primarily appointed in the Emergency Medicine Department at the IU School of Medicine my research is highly interdisciplinary. I span the basic sciences, medicine, and engineering to develop and translate unique pharmaceuticals and diagnostics always with the end goal of having a positive impact on people’s lives. Currently, I am the CEO, inventor and co-founder of Indiana Lysis Technologies LLC (co-founder Dr. Jeffrey Kline). ILT is a pharmaceutical startup through IU seeking to commercialize safer clot digesting therapies through nanoparticle delivery to treat various life threatening blood clots, including pulmonary embolism (blood clots in the lungs). Recently competing in the 2017 BioCrossroads New Venture Competition and the 2018 Notre Dame McCloskey Business Plan Competition Indiana Lysis Technologies won 3rd place (accompanying $10k award) and "Best Biotech Invention," respectively. This is an exciting beginning for something I believe will shape the future of how blood clots are treated clinically.